Metropolis Healthcare Share News - Latest Updates, Live News & More

Latest news about Metropolis Healthcare

Metropolis Healthcare Allots 9,960 Equity Shares Under Employee Stock Unit Plan Jan 13, 2026

Metropolis Healthcare Limited allotted 9,960 equity shares at ₹2.00 per share under its Restrictive Stock Unit Plan 2020, totaling ₹19,920.00. The allotment, approved on January 13, 2026, increases the company's total issued shares to 5,18,31,942 and share capital to ₹10,36,63,884.00. The shares carry pari-passu rights with existing equity shares, with 50% subject to a one-year lock-in period expiring January 13, 2027.

Metropolis Healthcare to expand genomics test menu to 500 in next two years Jan 13, 2026

Metropolis Healthcare launches Centre of Genomics to scale precision diagnostics in India Jan 13, 2026

Metropolis Healthcare Launches Two Accredited Genomics Labs in Delhi NCR and Mumbai Jan 13, 2026

Metropolis Healthcare Launches Advanced Genomics Center with Illumina's NovaSeq™ X Series Technology Jan 13, 2026

More news about Metropolis Healthcare

13Jan 26

Metropolis Healthcare Launches Centre of Genomics to Scale Precision Diagnostics in India

Metropolis Healthcare Limited launched its Centre of Genomics on January 13, 2026, deploying Illumina's NovaSeq™ X Series technology to advance precision diagnostics and genomic research in India. The Centre operates through two CAP-accredited laboratories in Delhi NCR and Mumbai, focusing on oncology, reproductive health, neurology, transplant immunology, and rare diseases. With over 220 validated genomic tests currently available, the company plans to expand its portfolio to more than 500 tests over the next two to three years, positioning itself as a strategic partner for global research and precision medicine initiatives.

05Jan 26

Metropolis Healthcare Shares Surge 4.6% Following Strong Q3 Business Update

Metropolis Healthcare shares gained 4.6% to ₹2,021.40 after reporting strong Q3 performance with 26% consolidated revenue growth driven by specialty testing and wellness segments. The company achieved 15% standalone revenue growth with successful acquisition integration and margin expansion despite seasonal weakness.

12Nov 25

Metropolis Healthcare Reports Strong Q2 FY26 Results with 23% Revenue Growth and Margin Expansion

Metropolis Healthcare Limited announced robust Q2 FY26 results with 23% year-over-year group revenue growth. Organic business revenue grew by 12%, while EBITDA margins improved to 26.8%. Patient volumes increased by 6% to 3.6 million, with test volumes also up 6% at 7.4 million. B2C and B2B segments showed strong growth at 11% and 14% respectively. The company added 200 collection centres in H1 FY26 and plans to add 300 more in H2. Core Diagnostics, a recent acquisition, improved from breakeven to high-single-digit margins. Metropolis is focusing on network expansion in Tier 2 and 3 cities, enhancing specialized testing capabilities, strengthening its TruHealth portfolio, and implementing AI-driven tools for improved efficiency.

06Nov 25

Metropolis Healthcare Targets Double-Digit Margins for Core Diagnostics, Expects 10-11% Volume Growth

Metropolis Healthcare aims for 70-100 bps organic business growth in FY26 with 10-11% volume growth. Core Diagnostics integration progresses, targeting breakeven by Q4FY25 and double-digit margins by FY26 end. Q2 results show strong performance with revenue up 22.7% to Rs 429 crore. The company's earnings call for Q2 FY26 is scheduled for November 6, 2025.

04Nov 25

Metropolis Healthcare Reports 23% Revenue Growth in Q2 FY26, Driven by Specialty Testing and Acquisitions

Metropolis Healthcare Limited, India's second-largest diagnostic chain, reported strong Q2 FY26 results with revenue up 23% YoY to ₹429.00 crore. EBITDA grew 19% to ₹109.00 crore, and PAT increased 13% to ₹53.00 crore. Patient volume rose 11% to 3.7 million, while test volume increased 12% to 7.9 million. B2C revenue grew 16% to ₹240.00 crore, and B2B revenue surged 33% to ₹189.00 crore. The company expanded in North India and Tier III cities, with recent acquisitions showing positive results. An interim dividend of ₹4.00 per equity share was declared.

04Nov 25

Metropolis Healthcare Reports Strong Q2 Performance with 23% Revenue Growth and Declares ₹4 Interim Dividend

Metropolis Healthcare's Q2 FY2025-26 results show strong growth with consolidated revenue increasing 22.7% to ₹4,291.91 million and net profit rising 13.3% to ₹528.90 million year-over-year. The company declared an interim dividend of ₹4 per share. Metropolis also completed three strategic acquisitions: DAPIC Metropolis Healthcare, Scientific Metropolis Pathology, and Dr. R.S. Patil's Ambika Pathology Laboratory.

04Nov 25

Metropolis Healthcare Declares Dividend, Reports Q2 EBITDA Growth, and Approves Stock Benefit Grants

Metropolis Healthcare has declared a dividend of Rs 4 per share and reported Q2 EBITDA of Rs 1.10 billion, up from Rs 899.00 million last year. The company's Nomination and Remuneration Committee approved stock benefits for eligible employees under three plans: Metropolis-Restrictive Stock Unit Plan 2020, Metropolis-Restrictive Stock Units Plan 2025, and Metropolis-Employees Stock Options Plan 2025. The plans have a minimum vesting period of 1 year, maximum vesting period of 4 years, and a maximum exercise period of 5 years from the vesting date. These schemes comply with SEBI regulations.

06Oct 25

Metropolis Healthcare Reports 23% Revenue Growth, Expands Regional Presence

Metropolis Healthcare achieved 23% year-on-year revenue growth in Q2 FY26, driven by preventive health check-ups and wellness offerings. TruHealth Wellness grew by 25%, while the Specialty Segment increased by 36%. B2C and B2B revenues rose by 16% and 34% respectively. The company reported improved core diagnostics margins and a net cash surplus of ₹55.00 crore. Metropolis completed a strategic acquisition in Kolhapur to enhance regional presence. Management focuses on margin increases and growth in wellness and specialty areas.

18Sept 25

Metropolis Healthcare Completes Acquisition of Ambika Pathology Laboratory

Metropolis Healthcare Limited has finalized the acquisition of Dr. RS Patil's Ambika Pathology Laboratory, effective September 18. The acquisition, executed as a going concern under a Business Transfer Agreement, includes deferred consideration terms. Ambika Pathology's operations have been integrated into Metropolis Healthcare's business structure. The company disclosed the acquisition details to stock exchanges in compliance with SEBI regulations.

16Sept 25

Metropolis Healthcare Launches Wholly Owned Healthcare Technology Subsidiary

Metropolis Healthcare Limited has incorporated a new wholly owned subsidiary, Metropolis Quality Solutions Private Limited, on September 15, 2023. The subsidiary will focus on healthcare technology, developing and dealing in tech-driven products and services. Metropolis Healthcare has subscribed to 10,000 equity shares at INR 10 each, maintaining 100% ownership. This strategic move aims to diversify offerings and capture new market segments in the healthcare ecosystem.

07Aug 25

Metropolis Healthcare Expands Footprint with Acquisition of Kolhapur's Ambika Pathology

Metropolis Healthcare Limited is set to acquire Dr. RS Patil's Ambika Pathology Laboratory in Kolhapur, Maharashtra for INR 17 crores. The acquisition, structured as a Business Transfer Agreement, includes the entire business as a going concern. Ambika Pathology, established in 1995, is NABL accredited with 12 patient touch points and reported revenues of INR 7.96 crore in FY 2024-25. This strategic move aims to strengthen Metropolis's presence in Western Maharashtra, establish a mini reference laboratory for surrounding districts, and enhance overall profitability in the region.

07Jul 25

Metropolis Healthcare Sees Robust Q1 Revenue Growth, Specialty Segment Shines

Metropolis Healthcare, a leading diagnostic services provider, has reported impressive Q1 financial results. The company's overall revenue increased by approximately 23% year-over-year. The specialty revenues segment showed exceptional performance, growing by over 35% compared to the same period last year. This strong growth across business segments, particularly in specialty services, indicates Metropolis Healthcare's expanding market presence and successful strategic focus on high-value diagnostic offerings.

04Jul 25

Metropolis Healthcare: Q1 Revenue Surges 23% YoY, Specialty Segment Shines

Metropolis Healthcare announced impressive Q1 financial results, with overall revenue growth of 23% year-over-year. The specialty segment showed exceptional performance, with a 35% increase in revenue. Other highlights include 13% revenue growth excluding acquisitions, 15% B2C revenue growth, and 20% growth in the TruHealth Wellness segment. The company's Core Diagnostics moved to positive margins, EBITDA improved quarter-over-quarter, and Metropolis remains debt-free.

14May 25

Metropolis Healthcare Reports Mixed Q4 FY23 Results with Profit Decline and Revenue Growth

Metropolis Healthcare's Q4 FY23 results show a 20.05% year-over-year decline in consolidated net profit to ₹291.00 crore, down from ₹364.00 crore in Q4 FY22. However, revenue increased by 4.23% to ₹345.00 crore from ₹331.00 crore in the same period last year. Compared to Q3 FY23, net profit decreased from ₹314.00 crore to ₹291.00 crore in Q4 FY23.

13May 25

Metropolis Healthcare: Q4 Profit Dips 19%, Revenue Rises 4%

Metropolis Healthcare reported Q4 FY25 results with mixed performance. Revenue increased 4.3% YoY to ₹345.30 crore, but profitability declined. EBITDA fell 22% to ₹62.30 crore, and net profit decreased 19.4% to ₹29.00 crore. Full-year highlights include 6% growth in patient volume, 7% in test volume, 17% in B2C revenue, and 12% in B2B revenue. The TruHealth portfolio showed strong revenue growth of 24%.

05May 25

Metropolis Healthcare to Announce Q4 FY2023 Results on May 13

Metropolis Healthcare Ltd., a leading Indian diagnostic services provider, will release its Q4 financial results for FY2022-23 on May 13, 2023. The announcement will offer insights into the company's performance for the quarter ending March 31, 2023, and potentially the entire fiscal year. Key financial metrics such as revenue, operating profit, net profit, and EPS are expected to be disclosed, providing valuable information for investors and analysts about the company's recent performance and position in the competitive diagnostics sector.

08Apr 25

Metropolis Healthcare Expands Footprint in North India with Strategic Acquisition in Dehradun

Metropolis Healthcare's subsidiary is set to acquire Dr. Ahujas' Pathology and Imaging Centre in Dehradun, Uttarakhand for ₹35 crore. The acquisition, expected to complete within 45 days, aims to strengthen Metropolis's presence in North India. This strategic move aligns with the company's expansion plans, enhancing its diagnostic capabilities in the region and capitalizing on the growing healthcare needs in tier-2 cities.

07Apr 25

Metropolis Healthcare Expands North India Presence with ₹35.01 Crore Acquisition of Dehradun's DAPIC

Metropolis Healthcare's subsidiary has acquired Dr. Ahujas' Pathology and Imaging Centre (DAPIC) in Dehradun for ₹35.01 crore in an all-cash deal. DAPIC, founded in 1990, is a leading diagnostic chain in Uttarakhand with NABL and NABH accredited labs. This acquisition is part of Metropolis' 'String of Pearls' strategy to expand in North India, increasing their revenue contribution from the region to 14-15%. The deal positions Metropolis as the second-largest diagnostic chain in Uttarakhand's ₹500 crore market.

09Mar 25

Metropolis Healthcare Expands North India Footprint with Strategic Acquisition

Metropolis Healthcare announces plans to acquire Scientific Pathology, an Agra-based diagnostic service provider, for a valuation between Rs 55 crore and Rs 83 crore. The deal, expected to close by March-end, aims to strengthen Metropolis' presence in Western Uttar Pradesh and North India. This strategic move follows the company's recent acquisition of Delhi-based Core Diagnostics, aligning with the ongoing consolidation trend in India's diagnostic services sector.

03Mar 25

Metropolis Healthcare Expands Footprint in Western UP with Strategic Acquisition

Metropolis Healthcare's subsidiary is acquiring Agra-based Scientific Pathology for ₹55-83 crore, strengthening its presence in Western Uttar Pradesh. The deal involves acquiring all labs and collection centers of Scientific Pathology in Agra and nearby towns. This move aims to establish Agra as a regional reference lab, accelerate B2C expansion, and enhance access to advanced diagnostics in the region. Scientific Pathology, founded in 1984, has a strong B2C focus with 90% revenue from walk-in patients and a FY24 turnover of ₹26 crore.